AstraZeneca PLC (CH:ZEG)

:ZEG

ZEG

AstraZeneca

RESEARCH TOOLSreports

Want to see CH:ZEG full AI Analyst Report?

AstraZeneca (ZEG) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZEG Analyst Ratings

Moderate Buy

12 Buy

2 Hold

1 Sell

Based on 15 analysts giving stock ratings to

AstraZeneca

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZEG Stock 12 Month Forecast

Average Price Target

CHF174.16

▲(43.26% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is CHF174.16 with a high forecast of CHF217.09 and a low forecast of CHF119.66. The average price target represents a 43.26% change from the last price of CHF121.57.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"118":"CHF118","143":"CHF143","168":"CHF168","193":"CHF193","218":"CHF218"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":217.087005,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF217.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":174.1584203976,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF174.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":119.662593,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF119.66</span>\n  </div></div>","useHTML":true}}],"tickPositions":[118,143,168,193,218],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,121.572,128.91930807692307,136.26661615384614,143.61392423076924,150.9612323076923,158.30854038461538,165.65584846153845,173.00315653846155,180.35046461538462,187.6977726923077,195.04508076923076,202.39238884615384,209.7396969230769,{"y":217.087005,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,121.572,125.61710926135385,129.6622185227077,133.70732778406153,137.75243704541538,141.79754630676922,145.84265556812306,149.8877648294769,153.93287409083075,157.9779833521846,162.02309261353844,166.0682018748923,170.11331113624615,{"y":174.1584203976,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,121.572,121.42512253846154,121.27824507692308,121.13136761538462,120.98449015384615,120.8376126923077,120.69073523076923,120.54385776923077,120.3969803076923,120.25010284615385,120.10322538461538,119.95634792307692,119.80947046153847,{"y":119.662593,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":121.572,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF217.09

Average Price TargetCHF174.16

Lowest Price TargetCHF119.66

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sarita Kapila

Morgan Stanley

CHF175.17

Buy

44.09%

Upside

Reiterated

04/13/26

AstraZeneca: Expanding COPD Biologic Opportunity With Tozorakimab Underpins Buy Rating and Long‑Term Growth Upside

Matthew Weston

UBS

CHF186.85

Buy

53.69%

Upside

Reiterated

04/10/26

UBS Sticks to Their Buy Rating for AstraZeneca (AZN)

Graham Parry

Citi

CHF180.48→CHF191.1

Buy

57.19%

Upside

Reiterated

04/10/26

AstraZeneca (AZN) Gets a Buy from Citi

Michael Leuchten

Jefferies

CHF191.1

Buy

57.19%

Upside

Reiterated

04/10/26

Jefferies Sticks to Their Buy Rating for AstraZeneca (AZN)

Richard Vosser

J.P. Morgan

CHF169.86

Buy

39.73%

Upside

Reiterated

04/07/26

J.P. Morgan Reaffirms Their Buy Rating on AstraZeneca (AZN)

Rajan Sharma

Goldman Sachs

CHF175.13→CHF176.23

Buy

44.96%

Upside

Reiterated

04/02/26

AstraZeneca (AZN) Receives a Buy from Goldman Sachs

Sachin Jain

Bank of America Securities

CHF175.17

Buy

44.09%

Upside

Reiterated

04/01/26

AstraZeneca: Buy Rating on Near‑Term Execution Strength and Undemanding Valuation Ahead of Pipeline‑Driven Re‑Rating

James Gordon CFA

Barclays

CHF175.17

Buy

44.09%

Upside

Reiterated

03/31/26

Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)

Emmanuel Papadakis

Deutsche Bank

CHF122.09

Sell

0.43%

Upside

Reiterated

03/30/26

Deutsche Bank Reaffirms Their Sell Rating on AstraZeneca (AZN)

Seamus Fernandez

Guggenheim

CHF169.86→CHF175.17

Buy

44.09%

Upside

Reiterated

03/29/26

Guggenheim Sticks to Its Buy Rating for AstraZeneca (AZN)

Steve Scala

TD Cowen

CHF190.14

Buy

56.40%

Upside

Reiterated

03/18/26

AstraZeneca: Diversified Growth, Compelling Valuation, and Manageable Risks Support Buy Rating

Justin Smith

Bernstein

CHF11.29→CHF217.64

Buy

79.02%

Upside

Reiterated

03/18/26

Bernstein Remains a Buy on AstraZeneca (AZN)

Luisa Hector

Berenberg Bank

CHF180.48

Buy

48.46%

Upside

Assigned

03/16/26

AstraZeneca (AZN) Gets a Buy from Berenberg Bank

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

02/12/26

DZ BANK AG Remains a Hold on AstraZeneca (AZN)

David Evans

Kepler Capital

CHF119.96

Hold

-1.32%

Downside

Reiterated

02/10/26

AstraZeneca (AZN) Receives a Hold from Kepler Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sarita Kapila

Morgan Stanley

CHF175.17

Buy

44.09%

Upside

Reiterated

04/13/26

AstraZeneca: Expanding COPD Biologic Opportunity With Tozorakimab Underpins Buy Rating and Long‑Term Growth Upside

Matthew Weston

UBS

CHF186.85

Buy

53.69%

Upside

Reiterated

04/10/26

UBS Sticks to Their Buy Rating for AstraZeneca (AZN)

Graham Parry

Citi

CHF180.48→CHF191.1

Buy

57.19%

Upside

Reiterated

04/10/26

AstraZeneca (AZN) Gets a Buy from Citi

Michael Leuchten

Jefferies

CHF191.1

Buy

57.19%

Upside

Reiterated

04/10/26

Jefferies Sticks to Their Buy Rating for AstraZeneca (AZN)

Richard Vosser

J.P. Morgan

CHF169.86

Buy

39.73%

Upside

Reiterated

04/07/26

J.P. Morgan Reaffirms Their Buy Rating on AstraZeneca (AZN)

Rajan Sharma

Goldman Sachs

CHF175.13→CHF176.23

Buy

44.96%

Upside

Reiterated

04/02/26

AstraZeneca (AZN) Receives a Buy from Goldman Sachs

Sachin Jain

Bank of America Securities

CHF175.17

Buy

44.09%

Upside

Reiterated

04/01/26

AstraZeneca: Buy Rating on Near‑Term Execution Strength and Undemanding Valuation Ahead of Pipeline‑Driven Re‑Rating

James Gordon CFA

Barclays

CHF175.17

Buy

44.09%

Upside

Reiterated

03/31/26

Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)

Emmanuel Papadakis

Deutsche Bank

CHF122.09

Sell

0.43%

Upside

Reiterated

03/30/26

Deutsche Bank Reaffirms Their Sell Rating on AstraZeneca (AZN)

Seamus Fernandez

Guggenheim

CHF169.86→CHF175.17

Buy

44.09%

Upside

Reiterated

03/29/26

Guggenheim Sticks to Its Buy Rating for AstraZeneca (AZN)

Steve Scala

TD Cowen

CHF190.14

Buy

56.40%

Upside

Reiterated

03/18/26

AstraZeneca: Diversified Growth, Compelling Valuation, and Manageable Risks Support Buy Rating

Justin Smith

Bernstein

CHF11.29→CHF217.64

Buy

79.02%

Upside

Reiterated

03/18/26

Bernstein Remains a Buy on AstraZeneca (AZN)

Luisa Hector

Berenberg Bank

CHF180.48

Buy

48.46%

Upside

Assigned

03/16/26

AstraZeneca (AZN) Gets a Buy from Berenberg Bank

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

02/12/26

DZ BANK AG Remains a Hold on AstraZeneca (AZN)

David Evans

Kepler Capital

CHF119.96

Hold

-1.32%

Downside

Reiterated

02/10/26

AstraZeneca (AZN) Receives a Hold from Kepler Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

3 Months

xxx

Success Rate

15/21 ratings generated profit

Average Return

+4.16%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +4.16% per trade.

1 Year

Matthew WestonUBS

Success Rate

36/38 ratings generated profit

Average Return

+18.02%

Copying Matthew Weston's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +18.02% per trade.

2 Years

xxx

Success Rate

20/21 ratings generated profit

Average Return

+27.80%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 95.24% of your transactions generating a profit, with an average return of +27.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZEG Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZEG has received 37 Buy Ratings, 2 Hold Ratings, and 6 Sell Ratings. ZEG average Analyst price target in the past 3 months is 174.16.

Each month's total comprises the sum of three months' worth of ratings.

ZEG Financial Forecast

ZEG Earnings Forecast

Next quarter’s earnings estimate for ZEG is CHF1.97 with a range of CHF1.88 to CHF2.08. The previous quarter’s EPS was CHF1.66. ZEG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ZEG has Performed in-line its overall industry.

ZEG Sales Forecast

Next quarter’s sales forecast for ZEG is CHF11.65B with a range of CHF11.26B to CHF11.98B. The previous quarter’s sales results were CHF12.32B. ZEG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ZEG has Performed in-line its overall industry.

ZEG Stock Forecast FAQ

What is CH:ZEG’s average 12-month price target, according to analysts?

Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 174.16.

What is CH:ZEG’s upside potential, based on the analysts’ average price target?

AstraZeneca PLC has 43.26% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AstraZeneca PLC a Buy, Sell or Hold?

AstraZeneca PLC has a consensus rating of Moderate Buy, which is based on 12 buy ratings, 2 hold ratings and 1 sell ratings.

What is AstraZeneca PLC’s share price target?

The average share price target for AstraZeneca PLC is 174.16. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF217.09 ,and the lowest forecast is CHF119.66. The average share price target represents 43.26% Increase from the current price of CHF121.57.

What do analysts say about AstraZeneca PLC?

AstraZeneca PLC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of AstraZeneca PLC?

To buy shares of CH:ZEG, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

AstraZeneca (ZEG) Stock Forecast & Price Target

ZEG Analyst Ratings

ZEG Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AstraZeneca

ZEG Analyst Recommendation Trends

ZEG Financial Forecast

ZEG Earnings Forecast

ZEG Sales Forecast

ZEG Stock Forecast FAQ

Detailed List of Analyst Forecasts